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Can montelukast correct immune dysregulation in preschool children with 
mild persistent asthma? 
 
INTRODUCTION 
Asthma is a complex and chronic inflammatory 
disorder associated with airway hyper-
responsiveness, chronic mucosal inflammation, and 
tissue remodeling of the airway structure mediated 
by Th2 (CD4+) cells.1  
It is the most common chronic disease of 
childhood. Its morbidity among preschoolers results 
in higher emergency department visits,  more sleep 
disturbances, and more restriction of family 
activities,2  while   among school children  there are 
more school absences and more hospitalizations 
than any other chronic illness.3  
Asthma incidence is higher during childhood.4 
Asthma prevalence is about 8.6% of children, and 
the greatest rate is in preschool children.3 However, 
more than half of all cases of persistent asthma start 
before the age of 3 years.5 
Cytokines play a key role in airway 
inflammatory disease of asthma by recruiting and 
activating multiple inflammatory cells in the 
respiratory tract, and hence modifies and 
determines the severity of the inflammatory 
responses in asthma.6 
In asthmatic patients, there is an increase in the 
number of CD4+ T helper cells in the airways, 
which are predominantly of the Th2 subtype, which 
are  characterized by secretion of Interleukin (IL-4,  
IL-13, IL-5 and IL-9).7 these cytokines increase 
IgE, eosinophils, and develop airway 
hyperresponsiveness.8 
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Interleukin-4 (IL-4) mediates proinflammatory 
functions in asthma. it is important for Th2 cell 
differentiation from uncommitted Th0 cells,6 
induction of the IgE isotype, switching of B cells, 
and promotion of eosinophil transmigration across 
endothelium and mucous secretion. 9 
IL-13 expression levels are increased in the 
airways of asthmatic patients10. IL-13  is a critical 
Th2 lineage cytokine. Being associated with asthma 
exacerbations11, IL-13  mimics IL-4 in inducing IgE 
secretion, and causes structural changes in the 
airways. 12 It also induces inflammation through 
stimulating the expression of chemoattractants 
CCL11 (eotaxin) from epithelial cells, and induces 
airway hyperresponsiveness (AHR) and mucous 
hypersecretion.13 Excessive IL-4 and IL-13 
production results in the production of Th2 clones, 
which enhances inflammation.14 
Interleukin (IL10) is an important 
immunoregulatory and anti-inflammatory cytokine 
that is reduced in asthmatic airways.14 It inhibits the 
synthesis of inflammatory proteins, cytokines (such 
as TNF-α, GM-CSF, IL-5, and several chemokines) 
that are over-expressed in asthma,  and also inhibits 
antigen presentation.15  
Interleukin IL-10 modulates cells involved in the 
allergic response, including TH2-cell activation, 
mast-cell,16  eosinophilic  function, 17 and IgG to 
IgE ratios.18 It promotes IgG4 production in B cells,  
also downregulates eosinophil survival, and inhibits 
IgE-mediated activation of mast cells. Moreover, it 
impairs dendritic cell (DC) maturation and reduces 
Th1 and Th2 cells stimulation.19 
Regulatory T cells (CD4+CD25+ Tregs) 
suppress harmful  immune responses in human 
beings,20 as well as in animal models.19 Two subsets 
of Treg (naturally occurring Treg cells and IL-10-
producing Tregs) have the potentials to suppress 
pathogenic Th2 responses. The airways of 
asthmatic patients show reduced expression of 
Foxp3 and deficiency of  CD25high Treg-suppressive 
function. 20-21  
Montelukast is a potent, specific leukotriene 
receptor antagonist. Administered once daily in a 
tablet form, Montelukast reduces the signs and 
symptoms of chronic asthma in adults and children 
with a tolerability profile similar to that of 
placebo.22-23  
Montelukast has a safety profile that can be used 
as a monotherapy in children because of the 
suboptimal delivery of inhaled medication, well-
controlled asthma, poor adherence to inhaled 
corticosteroids (ICS) and considered as an add-on 
therapy to patients insufficiently controlled by ICS, 
especially  children with decelerated growth.24 The 
drug also attenuates exercise-induced 
bronchoconstriction. 25, 26  
Stepwise approach to managing asthma in 
children 0-4 years recommends Montelukast in step 
2 (mild persistent asthma) as an alternative for 
inhaled corticosteroids (ICS), and in step 3&4, as 
an add-on therapy. 24, 27  
The aim of this study is to determine the effect 
of Montelukast in patients with mild persistent 
asthma by analyzing serum IL-13, IL-4 , IL-10, T-
helper cell  and T-regs (CD4/CD25) before and 
after six weeks of therapy. 
 
METHODS 
This is a prospective controlled study conducted 
among  sixty children, aged 2–5 years, who came to 
the Pediatric Outpatient Clinic in Ismailia 
University Hospital in the period from August 2015 
to August 2016. Forty children with asthma  
presented to pediatric outpatient clinic in acute 
exacerbation were evaluated with a screening 
questionnaire based on the Pediatric Asthma 
Quality of Life and were diagnosed  as mild 
persistent asthma. The questionnaire includes both 
daytime and nocturnal asthma symptom diary 
scales. 28, 29  
Asthma severity is determined  according to the 
Global initiative of Asthma (GINA). 30Twenty 
children matched for age and sex, with no history of 
allergic or respiratory disease, were chosen as the 
control group. Children were excluded if they have 
received a long-term controller therapy or systemic 
corticosteroids, or had  concomitant infections, or 
any chronic inflammatory disorders. 
A full clinical assessment, through history taking 
and physical examination, for each participant in 
both patients and control groups of the  study. 
Blood Samples were withdrawn from patients 
(before starting Montelukast)and controls  for  the 
following baseline hematological and 
immunological assessments: 
Complete  blood count, eosinophils counts 
measured by an automated hematology analyzer 
Coulter LH 750 (Beckman Coulter, USA) and 
expressed as the number of cells per cubic mm. 
Measurement of serum level of interleukin-4(IL-
4), IL-10 IL-13, using an ELISA kit (R & D 
systems) (Minneapolis, MN, USA). 
Flow cytometric assessment of  T helper and T 
regulatory cells  using a flow cytometer (FACs 
Calibur, BD, Bectom Dickinson). 
After diagnosis of mild persistent asthma, 
asthmatic children were started on once-daily  4 mg 
of  Montelukast (chewable tablet). They were 
followed up every two weeks for six weeks through 
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history taking and clinical examination for acute 
exacerbation and need for rescue medications. All 
the above investigations were repeated at the end of 
six weeks of  Montelukast therapy .  
 Flow cytometry procedure:  
Staining of (CD3, CD4, and CD25) cell markers 
was conducted according to the protocol of the 
manufacturing company of flow cytometer (FACS 
Calibur, BD, Bectom Dickinson (BD), USA); using 
conjugated monoclonal antibodies (MCAB) with 
phycoerythrin (PE), fluorescent isothyocyanate 
(FITC) and Allophycocyanin (APC). 
 
Immunophenotyping for T-regulatory cell:   
The reagents  for color analysis of T cell surface 
marker (CD3+ CD4+) consist of CD3-FITC and 
CD4-PE; for T-regulatory (cell surface staining 
CD4+CD25+ intracellular staining for  FoxP3 ) the 
reagents consisted of FITC conjugated anti-human 
CD4; PE conjugated anti-human CD25, and  APC- 
conjugated anti-human FOXP331. 
 
Ethical consideration: 
An informed written consent consistent with the 
ethical principles of the International Conference of 
Harmonization guideline  and Good Clinical 
Practice (ICH-GCP)32 was obtained from the 
guardians of all the cases. The study was approved 
by the local Ethics Committee of the Faculty of 
Medicine, Suez Canal University, Egypt. 
 
RESULTS 
Table 1 shows the demographic and laboratory data 
which demonstrate no statistical difference between 
patients and controls regarding the mean age, sex, 
BMI, and blood picture.  
The serum levels of IgE, IL4 and IL13 (Figs 1, 
2). And the counts of eosinophils, total 
lymphocytes, T cells (CD3+) and helper T cells 
(CD3+CD4+) were all increased with a statistically 
significant difference in  children with asthma more 
than the healthy control children. However, the 
serum levels of IL10 and Treg cells 
(CD4+CD25+FoxP3+) counts were significantly 
lower in asthmatic children (Table 2) and (Figs 
3,4). 
Montelukast treatment resulted in a significant 
decrease in serum levels of IgE, IL4 and IL13, 
whereas the serum level of IL10 significantly 
increased (Figs 1, 2, 3). The eosinophils cell count, 
total lymphocytes count, T cells (CD3+) and helper 
T cells count (CD3+CD4+) significantly decreased 
after treatment with Montelukast while Treg cell 
(CD4+CD25+ FoxP3+) count significantly increased 
in asthmatic children after treatment (Table 3) and 
(Fig4). 
In this study, we assessed the correlation 
between the cytokines and IgE and  immunological 
cells. There was a significant positive correlation of 
IgE with IL4 and IL13, whereas there was a 
significant negative correlation  between IgE and 
IL10. T lymphocytes had a significant positive 
correlation with IL13, while significant negative 
correlation with IL10 and no correlation with IL4. 
Helper T cells had a significant positive correlation 
with IL4 and IL13 however, it showed no 
correlation with IL10. T regulatory cells had no 
correlation with the studied cytokines (Table 4).  
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Table 2. Assessment of cytokine levels and immunological cell counts between asthmatic children before 
treatment and healthy control. 
 Asthmatic children Healthy control P value 
Total IgE IU/ml 384.60±128.92 59.45±15.95 <0.001* 
IL4 ng/l 161.99±31.43 44.17±10.4 <0.001* 
IL10 ng/l 4.87±.44 7.65±.93 <0.001* 
IL13 ng/l 102.07±35.01 17.04±2.57 <0.001* 
Lymphocyte x103/µl 4.434 ±0.6294 3.639±0.445 <0.001* 
Esinophil (cell/mm3) 403.8038±93.9107 179.51±41.69 <0.001* 
CD3+ (cell/mm3) 2180.28±484.12 1674.784±233.87 0.01* 
CD3+% 48.9±5.8 45.4±3.3 <0.001* 
CD3+CD4+ (cell/mm3) 1620.5± 249.29 1124.1±211.25 <0.001* 
CD3+CD4% 36.65± 3.36 30.86±3.99 <0.001* 
CD+4 CD25+ FoxP3+ (cell/mm3) 185.5± 25.7 201.7±32.8 <0.001* 
CD4+ CD25+ FoxP3+% 0.401±
 
.09144 0.5321±.06819 <0.001* 





Table 3. The Impact of Montelukast treatment on cytokine levels and immunological cell counts in 
asthmatic children 
 Before treatment After treatment P value 
Total IgE IU/ml 384.60±128.92 168.55±34.244 <0.001* 
IL4 ng/l 161.99±31.43 130±29.486 <0.001* 
IL10 ng/l 4.87±.44 6.9273±.86039 <0.001* 
IL13 ng/l 102.07±35.01 53.64±12.03 <0.001* 
Lymphocyte (Cell/mm3) 4.434 ±0.6294 3.887±0.5970 <0.001* 
Esinophil (cell/mm3) 403.8038±93.9107 266.848±35.20512 <0.001* 
CD3+ count (Cell/mm3) 2180.2828±484.122 1897.42±494.875 0.012* 
CD3+% 48.9±5.8 43.5±1.2 0.01* 
CD3+CD4+ (Cell/mm3) 1620.5±249.29 1342±306 <0.001* 
CD3+CD4% 36.65±.03365 31.1±.081 <0.001* 
CD4+ CD25+ FoxP3+% (Cell/mm3) 185±25 207.42±31.9 <0.001* 
CD4+ CD25+ FoxP3+ % 0.401±.0914 0.468±.038 <0.001* 





Table 4. Correlation between serum levels of cytokines with IgE, T lymphocytes and its subtypes in 
asthmatic children 




 r# P value r# P value r# P value r# P value 
IL4 0.673 <0.001* 0.112 0.321 0.264 0.018* 0.019 0.864 
IL10 -0.716 <0.001* -0.262 0.019* -0.077 0.638 0.108 0.342 
IL13 0.686 <0.001* 0.292 0.009* 0.38 0.001* -.0193 0.087 
#Pearson Correlation; *Statistically-significant 
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Figure 1. Serum levels of IL 4 in healthy control and asthmatic children before and after treatment. 
 
 
Figure 2. Serum levels of IL 13 in healthy control and asthmatic children before and after treatment. 
 
 
Figure 3. Serum levels of IL 10 in healthy control and asthmatic children before and after treatment. 
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Figure 4. Assessment of  T helper and T regulatory cells  by  flow cytometer. CD4 positive events gated 
within the lymphoid region (T helper) and dot plot was made with cells from this region showing CD4, 
CD25 and Foxp3 positive cells to assess the CD4+/CD25+/FoxP3+ coexpression (T regulatory ) from 
the T cells. 
 
DISCUSSION 
In our study serum L4 and IL13 and eosinophil 
count were high in all asthmatic children, findings 
which agree with those of other studies, which 
suggested that airway inflammation is the key to 
reversible airway obstruction in asthma.33  TH2 
cytokines (IL-4 and IL-13) play a great role in 
eosinophilic inflammation of asthmatic airways.34 
Correspondingly, Wills-Karp et al. 35 reported the 
role of TH2 cytokines in IgE synthesis by B cells; 
mucus production, bronchial fibrosis and airway 
hyper-responsiveness (AHR) in asthma. Levels of 
IL-13 and eosinophils numbers were high in sputum 
and bronchial biopsies from asthmatic patients.36 
Furthermore, eosinophil percentages were (29% 
and 23%) in severe and mild cases.37  
IgE acts as a mediator of the allergic response in 
asthma.38 Our results confirmed that all asthmatic 
children have increased IgE levels than their control 
counterparts. In a previous study, IgE level has 
been shown to be high in severe and mild asthma 
(43% and 50% respectively ).36-37 Specific IgE 
triggers eosinophils production and activates mast 
cells that differentiate T helper cells into Th2 cells 
which secrete IL-4, IL-5, IL-10 and IL-13 
cytokines.39-40 This explains the increased total 
lymphocyte count, and eosinophils cell count in  
our asthmatic children as compared to control. 
IL-10 controls immune tolerance to allergens. 
Asthma severity is inversely correlated with IL-10 
levels, Which inhibits Th1 and Th2 cell activation 
and acts as an anti-inflammatory cytokine.40 Also, it 
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inhibits eosinophilia by suppression of IL-5 and 
GM-CSF, direct effects on eosinophil apoptosis, 
and effects on cell proliferation through down-
regulation of  IL-1.41 
Our results show decreased serum levels of IL10 
in asthmatic children compared to healthy children. 
Diminished levels of IL-10 and elevated levels of 
proinflammatory   IL-17F and IL-33 were found in 
asthmatics.42,43 Patients with asthma  had 
significantly fewer IL-10 producing cells as 
compared to normal controls.44  
IL-10 is secreted by monocytes and T regulatory 
cells under the control of IL- 2 in response to 
allergens.41 Our low levels of IL10   might be due to 
the decrease of T regulatory cells (Tregs) count. 
However, both steroid therapy and allergen specific 
immunotherapy are known to elevate endogenous   
IL-10 levels as a target for treatment of asthma, due 
to its ability to inhibit IFN-γ and    IL-2 production 
in Th2 cells.41 Akdis et al., reported the IL-10 
reduction and increased IL-4 allergen-responsive T 
cells in allergic patients compared to non-atopic 
people. 45 
Our results show Treg cell (CD4+ CD25+ 
FoxP3+) count reduction, an increase of T cells 
(CD3+) and helper T cell (CD3+CD4+) counts in 
asthmatic children as compared to controls. Our 
findings agree with den Otter 46 who showed a 
strong correlation between high CD4+ cells (from 
bronchial biopsies) of asthmatic and a decline in its 
long-term lung function. 
Asthmatic patients have increased levels of IL-
13 and type 2 cytokines, reduction of 
bronchoalveolar lavage regulatory T-cell numbers 
and increase mast cell mediator levels.47  The 
inadequate production of immunoregulatory 
cytokines (e.g., transforming growth factor-b and 
IL-10 and conversion of regulatory T cells (Tregs) 
to Th2 effector cells all contribute in asthma 
pathogenesis. 48-50 
Function and numbers of CD4+CD25  T cell as 
well as Foxp3 mRNA in the lung (but not 
peripheral blood) were lower in asthmatic children 
as compared to non-asthmatics with cough,51 also 
Foxp3 protein expression was reduced  among 
asthmatic patients.52 
Montelukast decreases the bronchial tree hyper 
responsiveness in asthma. Sputum and peripheral 
blood eosinophils are reduced by treatment with 
Montelukast.53 After treatment with Montelukast, 
we observed a decreased  eosinophil, total 
lymphocyte, T cells (CD3+) and helper T cell 
(CD3+CD4+) counts.  
 
In-vitro studies showed that Montelukast given 
in high doses reduces IL-4, IL-5 and IL-13 levels in 
the lung.54 Montelukast was found to decrease IL-4 
mRNA expression in the lungs after challenge with 
allergens.55 Scientists found that allergic rhinitis 
children treated with Montelukast had a significant 
decrease of IL-4 and IL-13 and a significant 
increase of IFN-γ levels in their nasal lavage.56  In 
the current study, a  decrease in  the serum levels of 
IgE, IL4 and IL13, and elevation of the serum 
levels of IL10 after Montelukast usage was 
observed.  
T regulatory inhibits the immune responses 
progression, and limits its duration through IL-10 
and TGF-β.57 Montelukast can suppress the 
proliferation of inflammatory cells and decrease 
cytokines and inflammatory mediators while 
inhibiting airway remodeling or fibrosis.58 
The existing study investigates the role of Treg 
cells in the pathogenesis of mild asthma in children 
by detecting the levels of Tregs and cytokines in the 
peripheral blood. The serum levels of IL10, and 
Treg cells count decreased in asthmatic children as 
compared to the control group. Treatment with 
Montelukast has increased the Treg cell count in 
asthmatic children. This suggests that Treg cells are 
crucial in asthma, which may help future studies of 
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